Influence of COVID‐19 Vaccination on Treatment‐Related Adverse Events and Oncologic Outcomes of Nonmetastatic Nasopharyngeal Carcinoma

Documenti analoghi

• Impact of Clinical Surveillance on Outcomes of Locally Recurrent Nasopharyngeal Carcinoma
  di: Tsinrong Lee, et al.
  Pubblicazione: (2025)
• Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD‐L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma
  di: Kun Gao, et al.
  Pubblicazione: (2025)
• Prognosis After Discontinued Treatment due to Immune‐Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
  di: Hiromasa Ishihara, et al.
  Pubblicazione: (2025)
• EpCAM‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide
  di: Chien‐Fu Yeh, et al.
  Pubblicazione: (2025)
• Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review
  di: N. D. O'Donnell, et al.
  Pubblicazione: (2026)